Skip to content
Home/Companies/Pharma/Deallus
DE

Deallus

Pharma·UK·Exited 2024·Held 9yr

Deallus is a pharma services company, headquartered in United Kingdom.

Entry
2015
Hold
9yr
Exit
2024
Est. EV
–

Who owns Deallus?

Deallus was owned by ARCHIMED through MED I (2014 vintage) from 2015 to 2024, exited via Trade Sale.

Buyer identity available on Pro.

Hand-verified · updated 2026-04-21

ARCHIMED
Investor
ARCHIMED
MED I · 2014 · Buyout

Key facts

HQUnited Kingdom
SectorPharma Services
Exit Type
Trade Sale
Buyer
MOIC
–
Exit Year
2024

More from MED I

Other portfolio companies in the same fund.

Esperion Therapeutics
Active
Stago
Active
MedTechFrance· 2026
Fytexia
Exited 2023
HealthTechFrance· 2016
to
Micromed
Exited 2023
MedTechFrance· 2016
to
Natural Origins
Exited 2017
HealthTechFrance· 2016
to
Polyplus
Exited 2023
BiotechFrance· 2016
to

More PE-backed in Pharma

Comparable pharma deals from other GPs.

Delpharm
Active
SocadifFrance
Laboratoires Delbert
Active
SocadifFrance
Biogaran
Active
BC PartnersFrance· 2025
Dec Group
Active
capitonSwitzerland· 2025
Essential Pharma
Active
Penta CapitalUK· 2025
Forth Therapeutics
Active
Old College CapitalUK· 2025
Data refreshed weekly · Sourced from public filings